Frederick Howard, MD, explored the evolving intersection of artificial intelligence (AI), computational pathology, and precision breast oncology.
|Articles|June 14, 2013
When Do You Recommend Molecular Profiling of Tumors?
How often do you refer patients for molecular profiling of a malignant tumor? For which of the following tumor types would you be most likely to recommend molecular profiling? Answer these questions and more.
Advertisement
Advertisement
Related to this article
“Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon).
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical Oncology Congress 2026.
The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.
Long-term QUILT-3.032 data showed a 71% CR rate, with a median duration of 26.6 months with nogapendekin alfa inbakicept/BCG in BCG-unresponsive NMIBC.
The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk non–muscle invasive bladder cancer.
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer
2
NCCN Guidelines Position CAR T Cells in Early Relapsed Multiple Myeloma
3
Ris-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC
4
FDA Accepts NDA for UGN-103 in Recurrent Low-Grade Intermediate-Risk NMIBC
5